| Dr Mark F Hollingsworth, MD | |
|
2401 S 31st St, Temple, TX 76508-0001 | |
| (254) 724-2287 | |
| Not Available |
| Full Name | Dr Mark F Hollingsworth |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 2401 S 31st St, Temple, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033179593 | NPI | - | NPPES |
| 85357F | Other | TX | BLUE SHIELD |
| 1343808-06 | Medicaid | TX | |
| 1343808-05 | Other | TX | CSHCN |
| 180040813 | Other | TX | RR/MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | G5179 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark F Hollingsworth, MD Po Box 847408, Dallas, TX 75284-7408 Ph: (254) 724-2287 | Dr Mark F Hollingsworth, MD 2401 S 31st St, Temple, TX 76508-0001 Ph: (254) 724-2287 |
News Archive
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
IsoRay Inc., announced financial results for the third fiscal quarter ended March 31, 2011 underscoring significant improvements in quarterly sales revenue growth both sequentially and in the prior year quarter. Sales increased 17% in the period with the Company posting a 581% gain in gross profit compared to the prior year third quarter.
AlphaRx, Inc. announced positive preclinical results of GAI-122 injectable nanoemulsion, a Mitochondria-targeted neuroprotective drug candidate being developed for the treatment of Acute Ischemic Stroke. The results will be delivered as a podium presentation during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon July 10 - 14, 2010.
A new technique for producing artificial bone implants has been developed by Korean researchers. Published in the journal Science and Technology of Advanced Material (STAM), the technique combines two methods to approximate both types of bone tissue. By mimicking natural bone, it is hoped the implant material will better complement the natural regeneration process.
› Verified 2 days ago
Dr. Derrick S. Fung, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 Fax: 254-724-7791 | |
Dr. Austin Wei Chang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1905 Sw H K Dodgen Loop, Temple, TX 76502 Phone: 254-773-7785 Fax: 254-778-7197 | |
Kendall Bicknell, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1901 Veterans Memorial Dr, Temple, TX 76504 Phone: 254-743-0728 | |
Dr. J Paul Dieckert, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Corey Breland Parish, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Todd Bradley Gorden, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1618 Canyon Creek Dr, Suite 120, Temple, TX 76502 Phone: 254-791-2020 Fax: 254-791-2025 |